Replies to post #111423 on Biotech Values

[DewDiligence]

How will TEVA spin the raw egg on their faces when Copaxone goes generic? Can't wait to hear it.

The PR is probably written already; it will say that Teva has established “preferred” status with most major US health insurers to ensure that the impact to branded Copaxone sales will be minimal. The sell-side analysts will, of course, parrot this assertion in their reports.